About Vor Biopharma Inc.

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Employees: 76
Price: $19.38
Previous close: $19.37
Market capitalization: $1.05B
Volume: 2,764,311
P/E ratio: -0.06
52-week low: $6.50
52-week high: $49.95

Additional performance and financial-statement views load in the interactive application.

Market information is provided for research and visualization and is not investment advice.